Amid outcry, KaloBios may jack the drug’s price and make millions off FDA voucher.
Source: In comeback bid, Shkreli’s old company gets OK to buy life-saving drug | Ars Technica
Amid outcry, KaloBios may jack the drug’s price and make millions off FDA voucher.
Source: In comeback bid, Shkreli’s old company gets OK to buy life-saving drug | Ars Technica